Scarica l'app Stockscreener
55.92
0.94%
-0.53
Dopo l'orario di chiusura:
55.91
-0.01
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$56.45
Aprire:
$56.49
Volume 24 ore:
1.05M
Relative Volume:
0.42
Capitalizzazione di mercato:
$6.89B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
18.52
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-3.00%
1M Prestazione:
+5.89%
6M Prestazione:
-0.04%
1 anno Prestazione:
+3.48%
Intervallo 1D:
$55.64
$56.66
Intervallo di 1 settimana:
$55.64
$58.56
Portata 52W:
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
55.92 | 7.10B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
What analysts say about Halozyme Therapeutics Inc. stockConsistent high-yield stocks - jammulinksnews.com
Is Halozyme Therapeutics Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com
What drives Halozyme Therapeutics Inc. stock priceExplosive capital gains - jammulinksnews.com
Halozyme Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Beginners Guide - PrintWeekIndia
Published on: 2025-07-18 13:49:29 - jammulinksnews.com
Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $60.00 - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
How Halozyme Therapeutics Inc. stock performs during market volatilityFree AI-Powered Stock Predictions - beatles.ru
Halozyme Therapeutics: A 20% CAGR Growth Story Powered by ENHANZE, Litigation Upside, and Undervalued M&A Potential - AInvest
Halozyme Therapeutics' strategic adoption - MarketScreener
Halozyme Therapeutics (HALO): Navigating Regulatory Crosscurrents to Seize Long-Term Value - AInvest
Halozyme Therapeutics Downgraded Amid Concerns Over Long-Term Value. - AInvest
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) (HALO) - Seeking Alpha
Halozyme Therapeutics: CEO Stock Sales vs. Robust Pipeline and Financial Momentum - AInvest
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises By Investing.com - Investing.com South Africa
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises - Investing.com Nigeria
Halozyme stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com Canada
Goldman Sachs Resumes Coverage of Halozyme (HALO) with Neutral R - GuruFocus
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga
Halozyme Therapeutics Added to Russell 1000® Index - Eastern Progress
Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday - MSN
Halozyme Therapeutics (HALO): A Momentum Stock to Consider - AInvest
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics Added to Russell 1000® Index | HALO Stock News - GuruFocus
Halozyme Therapeutics: A Catalyst-Fueled Ascension to the Russell 1000 - AInvest
Halozyme therapeutics added to Russell 1000 index By Investing.com - Investing.com South Africa
Halozyme therapeutics added to Russell 1000 index - Investing.com
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve
Breakthrough for CIDP Patients: EU Green Lights First Novel Treatment in 3 DecadesHalozyme Partnership Delivers - Stock Titan
Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media
Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN
TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria
Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
Merck gains U.S. patent office support in Keytruda dispute - MSN
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):